Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Melanoma
New melanoma study findings have been published by scientists at Melanoma Center
August 27th, 2008
According to recent research from the United States, "Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2) are 2 cytokines with distinct mechanisms of action that complement one another in the adjuvant management of melanoma. Forty-five patients with high-risk melanoma were enrolled in an open-label, single-arm, phase II clinical trial to examine the safety, tolerability, and effectiveness of this combination." "After potentially curative surgery, each patient received 12 months of GM-CSF 125 mu g/m(2)/d subcutaneously (SC) for 14 days followed by IL-2, 9 million IU/m(2)/d SC for 4 days (given every other cycle from months 7-12), followed...
Source: Vaccine Weekly (2008-08-27)
|
